XML 42 R27.htm IDEA: XBRL DOCUMENT v3.25.1
DISCONTINUED OPERATIONS (Tables)
 3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Discontinued Operations The results of operations from discontinued operations during the three months ended March 31, 2024, have been reflected as loss from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consisted of the following:
Three Months Ended
March 31,
(In thousands)
2024
Major line items constituting pretax income (loss) of discontinued operations
Revenues:
Total revenues$7,490 
Operating expenses:
Cost of product revenue1,563 
Research and development5,674 
Selling, general and administrative2,402 
Total operating expenses9,639 
Loss from discontinued operations, net of income taxes$(2,149)
Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition
The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three months ended March 31, 2024 (in thousands):
Three Months Ended
March 31,
2024
Revenue from Janssen Collaboration Agreement:
Over Time:
Research and Development Services$971 
Clinical Supply Services2 
Total Revenue from Janssen Collaboration Agreement$973 
The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three months ended March 31, 2024 (in thousands):
Three Months Ended
March 31, 2024
MundipharmaMelinta
Revenue from Collaboration, License and Commercial Agreements:
Point in Time:
License of Intellectual Property - upon milestone achieved$813 $— 
Product Revenue2,826 — 
Royalty Revenue26 76 
Over Time:
Research and Development Services3,266 317 
Clinical Supply Services166 — 
Total Revenue from Collaboration, License and Commercial Agreements$7,097 $393